COVAX Guidance, Analysis, Reports

Emergency use of unproven clinical interventions outside clinical trials: ethical considerations – WHO
12 April 2022 :: 60 pages
Overview
This document is intended to provide policy-makers, authorities in charge of the prevention and management of a public health emergency, such as ministries of health, national regulatory authorities and national disaster management agencies, health-care workers, ethics committees and others, with:
an updated version of the ethical framework for use of unproven clinical interventions outside clinical trials during public health emergencies (the MEURI ethical framework), general and operational recommendations for implementing the framework and • answers to questions that stakeholders may raise.

Equitable access to COVID-19 tools – WHO
Aligning the private sector with national response efforts
12 April 2022 :: 28 pages
Overview
COVID-19 has reinforced the need for whole-of-society and whole-of-government approaches to the pandemic response. This has tested the foundation of public and private sector relations in healthcare, and either nurtured or exacerbated trust. In many instances, the private sector has demonstrated solidarity and delivered critical essential and COVID-19-related health services and products. However adverse behaviours have also featured. These have exacerbated the State’s duty to ‘protect’ the right to health, improve health security and system resilience for universal health care. The pandemic has further exposed the need for robust governance of health systems. This is good for both the private and public sectors, but most importantly, consumers, including those most likely to be left behind. This rapid review seeks to understand why and where there has been swift and proactive action to build better governance of national COVID-19 response, to cross-countries lessons sharing on how to govern the private sector in health to maximize the COVID-19
response.